概括
模仿人类胃癌抗原的抗异型抗体 (Ab2) 诱导形成具有与原始抗体 (Ab1) 相同的结合性质的抗异型抗体 (Ab3). 这表明Ab2在癌症免疫治疗中的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 针对瘤抗原的单克隆抗体 (mAbs) 在癌症研究中至关重要.
- 反型抗体 (Ab2) 可以模仿抗原或抗体的表位.
- 了解Ab2诱导的免疫反应是开发新型癌症疗法的关键.
研究的目的:
- 使用抗异形抗体 (Ab2) 调查抗异形抗体 (Ab3) 的生成和特征.
- 确定Ab3是否可以复制原始单克隆抗体 (Ab1) 对人类胃癌抗原的结合特异性.
- 通过诱导类似于瘤抗原的免疫反应来探索Ab2在癌症治疗中的潜力.
主要方法:
- 用针对特定异型的山羊抗异型抗体 (Ab2) 免疫BALB/c小鼠和子.
- 产生和表征单克隆抗抗异型抗体 (Ab3).
- 结合性测试比较Ab1,Ab2和Ab3的特异性和特异性与瘤抗原.
主要成果:
- 一个单克隆Ab3 (IgG1同型) 从免疫小鼠中成功生成.
- 来自小鼠和子的Ab3表现出与Ab1相同的结合特异性和类似的激情,结合相同的胃肠癌相关抗原.
- Ab2成功诱导了抗原特定的Ab3,这表明它携带了瘤抗原的"内部图像".
结论:
- 抗类型抗体 (Ab2) 可以诱导形成抗原特异性抗类型抗体 (Ab3),模仿原始抗体的结合特性.
- 通过引起针对瘤相关抗原的免疫反应,Ab2证明了作为疫苗候选人的潜力.
- 这些发现支持使用抗类型抗体来调节癌症患者的免疫反应.
相关概念视频
Antibody Structure
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Cross-reactivity
Overview
Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antigens Involved in Adaptive Immunity
An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Antibody Actions
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


